Gary Graf, APRN
Nurse Practitioner · Topeka, KSNPI 1053482174
Payments from drug & device makers
Across 1,937 payments — averaging $374.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$337K
- Averitas Pharma Inc.$145K
- Novo Nordisk$105K
- Bayer$50K
- Ascensia Diabetes Care US Inc.$49K
- GRT US Holding, Inc.$22K
- plus $19K from 22 others
What the payments were for
- Consulting fees$28,3414%
- Speaking & faculty fees$599,48383%
- Travel & lodging$73,50410%
- Food & beverage$24,8423%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 962 | $336,903 |
| Averitas Pharma Inc. | 325 | $145,070 |
| Novo Nordisk | 207 | $105,421 |
| Bayer | 68 | $49,845 |
| Ascensia Diabetes Care US Inc. | 70 | $48,658 |
| GRT US Holding, Inc. | 59 | $21,711 |
| Senseonics, Incorporated | 15 | $8,000 |
| Mannkind Corporation | 18 | $2,804 |
| Corcept Therapeutics | 42 | $1,884 |
| Xeris Pharmaceuticals, Inc. | 31 | $1,065 |
| Amgen(2 entities) | 17 | $905 |
| Sanofi-aventis U.S. LLC | 17 | $806 |
| Zealand Pharma US, Inc. | 12 | $548 |
| Boehringer Ingelheim | 25 | $480 |
| Novartis | 10 | $424 |
| Abbott | 5 | $338 |
| AstraZeneca | 11 | $255 |
| Dexcom, Inc. | 4 | $243 |
| AbbVie | 13 | $234 |
| Insulet Corporation | 15 | $228 |
| Medtronic | 2 | $98 |
| Esperion Therapeutics, Inc. | 1 | $93 |
| BETA Bionics, Inc. | 1 | $80 |
| Antares Pharma, Inc. | 3 | $53 |
| Sequel Med Tech, LLC | 1 | $26 |
| Merck | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$287,385
- Qutenza$160,213
- RYBELSUS$57,574
- Kerendia$48,156
- Ozempic$33,909
- EVERSENSE E3 SMART TRANSMITTER KIT$16,122
- HUMULIN$11,500
- TRULICITY$9,500
- Eversense$8,000
- EVERSENSE 365 SENSOR KIT (RETAIL)$6,960
- EVERSENSE E3 SENSOR KIT - RETAIL$6,266
- BAQSIMI$4,995
- V-GO$1,450
- Korlym$1,160
- AFREZZA$900
- GVOKE HYPOPEN$472
- TEPEZZA$470
- ZEGALOGUE$425
- SOLIQUA 100/33$275
- LEQVIO$231
How this compares
$726,229 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 498 | $719,265 |
| MounjaroTirzepatide | 291 | $368,794 |
| JardianceEmpagliflozin | 267 | $246,972 |
| KorlymMifepristone | 11 | $237,392 |
| Tresiba Flextouch U-200Insulin Degludec | 164 | $182,915 |
| TrulicityDulaglutide | 144 | $169,851 |
| Tresiba Flextouch U-100Insulin Degludec | 165 | $118,173 |
| FarxigaDapagliflozin Propanediol | 75 | $76,213 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $63,444 |
| KerendiaFinerenone | 70 | $58,694 |
| Victoza 3-PakLiraglutide | 36 | $51,865 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 127 | $48,640 |
| AfrezzaInsulin Regular, Human | 33 | $42,570 |
| Novolog FlexpenInsulin Aspart | 124 | $39,270 |
| JanuviaSitagliptin Phosphate | 37 | $37,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog | $105,421 | $781,836582 claims |
| Lilly USA, LLCMounjaro, Trulicity | $336,903 | $538,646435 claims |
| Boehringer IngelheimJardiance, Tradjenta | $480 | $270,010290 claims |
| Corcept TherapeuticsKorlym | $1,884 | $237,39211 claims |
| AstraZenecaFarxiga | $255 | $76,21375 claims |
| BayerKerendia | $49,845 | $58,69470 claims |
| Mannkind CorporationAfrezza | $2,804 | $42,57033 claims |
| MerckJanuvia | $25 | $37,96937 claims |
| Sanofi-aventis U.S. LLCLantus | $806 | $9,05847 claims |
| AbbVieSynthroid | $234 | $7,16190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Topeka
- Shannon GreggTopeka$140K
- Kelli BradburyTopeka$20K
- Laura WelbornTopeka$8K
- Alexandra HeerenTopeka$8K
- Amie WunderTopeka$8K
- Jayda RuppTopeka$7K
- Lora UtechTopeka$6K
- Sarah FitzmauriceKansas City$247K
- Anna ShortRoeland Park$215K
- Morteza RabiiOverland Park$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.